Designing a multi-epitope mRNA vaccine to combat human metapneumovirus based on consensus sequence using reverse...

Area of Science:

• Vaccinology
• Immunoinformatics
• Molecular Biology

Background:

• Human metapneumovirus (HMPV) is a significant cause of severe respiratory illness in young children, leading to numerous hospital admissions.
• Currently, there are no licensed vaccines or specific therapies available for HMPV infection, highlighting an urgent need for preventive strategies.

Purpose of the Study:

• To design and computationally evaluate a novel multi-epitope mRNA vaccine against Human metapneumovirus (HMPV).
• To identify conserved, non-toxic, and non-allergenic viral epitopes for vaccine development.

Main Methods:

• Consensus sequences of HMPV surface proteins were derived from 782 genomes.
• Immunoinformatic approaches were used to identify immunodominant T-cell and B-cell epitopes.
• Epitopes were combined with adjuvants and linked into a multi-epitope construct for mRNA vaccine design.
• In silico analyses included physicochemical stability, molecular docking, molecular dynamics, immune simulations, mRNA secondary structure prediction, and cloning into a pVAX1 vector.

Main Results:

• Identified conserved, antigenic, non-toxic, and non-allergenic epitopes across HMPV clades.
• The designed multi-epitope mRNA vaccine construct demonstrated stability under physiological conditions.
• In silico analyses predicted robust humoral and cellular immune responses, stable interactions with immune receptors, and efficient mRNA translation.
• The final vaccine construct was successfully cloned in silico into the pVAX1 vector.

Conclusions:

• The developed multi-epitope mRNA vaccine is a promising candidate for preventing Human metapneumovirus (HMPV) infections.
• Computational validation supports the potential efficacy and stability of this novel vaccine strategy.